Diplomat Pharmacy,Inc. (NYSE:DPLO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

On March 31, 2017, Diplomat Pharmacy, Inc., a Michigan corporation, its subsidiaries (collectively, the “Company”), and Celgene Corporation, a Delaware corporation (“Celgene”) entered into a Pharmacy Distribution and Services Agreement (the “Agreement”), to be effective July 1, 2017 (the “Effective Date”). On the Effective Date, the Agreement will replace the Company’s current agreement with Celgene, as amended, which is set to expire on June 30, 2017 (the “Current Agreement”). The Agreement sets forth the terms and conditions on which the Company will purchase specialty drugs from Celgene and provide certain services in connection with dispensing prescriptions for such specialty drugs following the expiration of the Current Agreement.

The Agreement is substantially similar to the Current Agreement, except that the Agreement (i) has a term beginning on the Effective Date and ending on June 30, 2019 (subject to each party’s right to terminate for convenience with at least 90 days’ notice), (ii) revises the fees charged for certain services performed by the Company in connection with the Company’s dispensing of prescriptions for the purchased specialty drugs, and (iii) revises the per prescription payouts collected by the Company in the event it meets certain performance targets negotiated with Celgene.

Until the Effective Date, the Current Agreement remains in full force and effect.